RESOURCES

/

FIND A SPECIALIST

/

CONTACT

The FDA Needs to Hear Your Voice

The FDA is currently reviewing a potential treatment for focal segmental glomerulosclerosis (FSGS). Sign our letter to the FDA to ensure that the lived experiences of patients and caregivers are part of this decision. Your journey with FSGS matters. Your voice matters. And right now, it matters more than ever that you are heard. Sign NephCure's letter to the FDA by 2/18. 

Sign now

Rebecca Cook

Director, Strategic Operations

Rebecca "Birdie" Cook is NephCure’s Director of Strategic Operations. She rejoined the NephCure team in 2017 and hopped right back in! Rebecca grew up in Maryland and graduated from Bryn Mawr College in 2015 with a double major in Sociology and International Studies. While she used to work with our pharmaceutical partners, her role has shifted to be focused on internal operations and supporting NephCure's amazing staff! In her free time, she can be found cooking up a storm of vegetarian cuisine with local produce and taking pictures of her goofy tabby cat, Roland.

Boston, MA

Related News

NEWS

Letter to the NephCure Community: Update on FDA Decision About Sparsentan for FSGS

NEWS

NephCure Unveils New Mission Focusing on New Era of Access for Rare Kidney Disease Patients

NEWS

The FDA Grants Accelerated Approval to VOYXACT, a New Treatment Option for Adults with IgA Nephropathy

NEWS

NephCure Wins Silver at the Fifth Annual Anthem Awards for Kidney Month Campaign

Sign up to get NephCure’s latest updates.

SIGN UP
This field is for validation purposes and should be left unchanged.